ReviewJournal of clinical microbiology2020
Fourth-Generation QuantiFERON-TB Gold Plus: What Is the Evidence?
Review in Journal of clinical microbiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 1 synthesis or guideline pooled it, 83 citations in OpenAlex.
- Comparing the diagnostic performance of QuantiFERON-TB Gold Plus with QFT-GIT, T-SPOT.TB and TST: a systematic review and meta-analysis.BMC infectious diseases · 2023Pooled it
- Evaluating the Cepheid Xpert TB/LTBI Research-Use-Only Assay for Detection of Active and Latent Mycobacterium tuberculosis Infection.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- A multiplex Mtb-specific FluoroSpot assay measuring IFNγ, IL-2, and TNF-secreting cells can improve accuracy and differentiation across the tuberculosis spectrum.Journal of clinical microbiology · 2025Article
- Characteristics of indeterminate QuantiFERON-TB Gold PLUS results in pediatric lupus nephritis at Beijing Children's Hospital, 2023-2024.BMC nephrology · 2025Article
- Giant Bilateral Iliopsoas Abscesses, Secondary to Pott's Disease: Challenging Diagnostic-Therapeutic Protocol Management (Modern and Innovative Open Approach Technique Through J.L. Petit Triangle)-A Case Report and Literature Review.Diagnostics (Basel, Switzerland) · 2025Article
- Immune Sensitization toPathogens (Basel, Switzerland) · 2025Article
- Screening for Latent Tuberculosis Across Chronic Kidney Disease Stages Using Interferon-Gamma Release Assay: Findings from a National Infectious Disease Institute in Thailand.Tropical medicine and infectious disease · 2025Article
- Preliminary performance of the VIDAS TB-IGRA as an aid in the diagnosis of individuals infected withJournal of clinical microbiology · 2025Article
- The Recent Development in the Diagnosis ofSmart medicine · 2025Review
- Preliminary evaluation of a new prototype interferon-gamma release assay for the detection of Mycobacterium tuberculosis-specific T-cell responses in patients with tuberculosis.Folia microbiologica · 2025Article
- Evaluation of an interferon-gamma release assay for early detection of lumpy skin disease virus infection and vaccination in cattle.Microbiology spectrum · 2025Article
- Impact of an analytical intervention to assure the accuracy of LIAISON QuantiFERON-TB Gold Plus results.Journal of clinical microbiology · 2025Article
- Comparative evaluation of QuantiFERON-TB gold in-tube plus for Mycobacterium tuberculosis infection among adolescents in China.BMC public health · 2025Article
- Multiple cytokine analysis based on QuantiFERON-TB gold plus in different tuberculosis infection status: an exploratory study.BMC infectious diseases · 2024Article
- Evaluation of SARS-CoV-2 interferon gamma release assay in BNT162b2 vaccinated healthcare workers.PloS one · 2024Article
- Prevalence of indeterminate tuberculosis interferon-gamma release assays in COVID-19 patients: Systematic review and meta-analysis.Health science reports · 2023Article
- Accuracy of QuantiFERON in active tuberculosis suspects with comorbidities and nontuberculous mycobacterial infection in Northern California.Journal of clinical microbiology · 2023Article
- Screening for Latent Tuberculosis Infection in Solid Organ Transplant Recipients to Predict Active Disease: A Systematic Review and Meta-Analysis of Diagnostic Studies.Open forum infectious diseases · 2023Article
- Inflated Gamma Interferon Response with QuantiFERON-TB Gold Plus Using the Automated Liaison XL Analyzer: a Testing Algorithm To Mitigate False-Positive Results in Low-Incidence Settings.Journal of clinical microbiology · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
QuantiFERON-TB Gold Plus (QFT-Plus) is the latest generation of interferon gamma release assays (IGRAs) to receive approval from the U.S. FDA, replacing its predecessor, QuantiFERON-TB Gold In-Tube (QFT-GIT). The novelty of QFT-Plus is that it elicits a response from CD8 T cells, in addition to CD4 T cells, thus collecting a broader response from T-cell subsets than QFT-GIT. It was developed with the aim to improve the detection of latent tuberculosis infection (LTBI), especially among recently exposed contacts, immunocompromised hosts, and young children. In this minireview, we summarize the performance of QFT-Plus compared with that of QFT-GIT among active tuberculosis (TB) patients (a surrogate for LTBI patients), high-risk populations, and low-risk individuals based on recent publications. Studies comparing QFT-Plus to QFT-GIT currently do not support the superior performance of QFT-Plus in individuals with active TB and LTBI. The difference in sensitivity between QFT-Plus and QFT-GIT in active TB patients was not significant in nearly all studies and ranged from -4.0 to 2.0%. Among high-risk groups, the agreement between QFT-Plus and QFT-GIT was 89.9 to 96.0% (kappa coefficient range, 0.80 to 0.91). The specificity in the low-risk population was slightly lower for QFT-Plus than for QFT-GIT, with the difference ranging from -7.4 to 0%. Further studies are needed to accurately evaluate the sensitivity of QFT-Plus in immunocompromised hosts and children. In addition, further evidence is required to validate a modified interpretation of QFT-Plus for the identification of false-positive results in low-risk health care workers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.